PTEN loss in thyroid cancer can lead to resistance to BRAF inhibitors due to the interconnected nature of the PI3K/AKT pathway, which is regulated by PTEN, and the MAPK pathway, which is driven by mutant BRAF. This evidence concerns the gene AKT1 and thyroid gland carcinoma.